Alcon Inc. (ALC)
$
78.44
-0.39 (-0.50%)
Key metrics
Financial statements
Free cash flow per share
3.1080
Market cap
38.8 Billion
Price to sales ratio
3.8092
Debt to equity
0.2373
Current ratio
2.1181
Income quality
1.9747
Average inventory
2.4 Billion
ROE
0.0477
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
The financial data pertains to the fiscal year 2024. During this period, the company incurred an income tax expense of $238,000,000.00 indicating its tax obligations. The net total of other income and expenses is -$157,000,000.00 reflecting non-core financial activities. Furthermore, the gross profit ratio is 0.56 reflecting the efficiency of the company's production and sales operations. The net income ratio is 0.10 reflecting the company's profitability margin. Alcon Inc. is dedicated to advancing eye care through its Surgical and Vision Care segments, offering a comprehensive range of products such as intraocular lenses, surgical equipment, diagnostic tools, contact lenses, and ocular health solutions. Founded in 1945 and headquartered in Geneva, Switzerland, Alcon is committed to innovation and quality, ensuring that healthcare professionals and patients benefit from its advanced technologies and eye care solutions. The stock is reasonably priced at $77.25 appealing to a broad range of investors. With a mid-range market capitalization of $38,796,424,000.00 the company is a steady performer. Additionally, the stock has an average trading volume of 1,629,476.00 indicating moderate liquidity. Alcon Inc. is a key player in the Medical - Instruments & Supplies industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth. The company’s strategic focus on enhancing vision care and developing advanced surgical solutions positions it as a vital contributor in the eye care market, meeting the diverse needs of eye care professionals and patients worldwide.
Is Alcon Inc. (ALC) a good investment?
Investing in Alcon Inc. (ALC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bearish outlook. Always conduct your own research before investing.
What is Alcon Inc. (ALC)'s stock forecast?
Analysts predict Alcon Inc. stock to fluctuate between $71.55 (low) and $99.20 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Alcon Inc.'s market capitalization?
As of 2026-02-10, Alcon Inc.'s market cap is $38,796,424,000, based on 494,600,000 outstanding shares.
How does Alcon Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Alcon Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Alcon Inc. pay dividends?
Alcon Inc. pays dividends. The current dividend yield is 0.36%, with a payout of $0.33 per share.
How can I buy Alcon Inc. (ALC) stock?
To buy Alcon Inc. (ALC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALC. Place an order (Market, Limit, etc.).
What is the best time to invest in Alcon Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Alcon Inc. perform in the last earnings report?
Revenue: $9,911,000,000 | EPS: $2.06 | Growth: 4.04%.
Where can I find Alcon Inc.'s investor relations reports?
Visit https://www.alcon.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Alcon Inc.?
You can explore historical data from here
What is the all-time high and low for Alcon Inc. stock?
All-time high: $101.10 (2024-09-12) | All-time low: $55.21 (2022-10-13).
What are the key trends affecting Alcon Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
GENEVA--(BUSINESS WIRE)--Alcon Completes $750 Million Share Repurchase Program.
seekingalpha.com
Alcon Inc. (ALC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
businesswire.com
GENEVA--(BUSINESS WIRE)--Alcon Terminates Agreement to Acquire STAAR Surgical.
benzinga.com
STAAR Surgical Company (NASDAQ: STAA) announced Tuesday that it did not receive the necessary stockholder votes to approve the merger agreement with Alcon Inc. (NYSE: ALC) at the Special Meeting of Stockholders.
businesswire.com
GENEVA--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 a.m. PST. A live webcast of the conference will be available at investor.alcon.com/news-and-events/events-and-presentations. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve.
prnewswire.com
Expresses Disappointment in the Board's and Management's Continued Pursuit of Ill-advised Deal CHARLOTTE, N.C. , Dec. 17, 2025 /PRNewswire/ -- Defender Capital ("Defender" or "we"), a long-term shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) owning approximately 1.5% of the Company's outstanding common stock, today issued the following statement reiterating its intention to vote AGAINST the Company's proposed sale to Alcon Inc. ("Alcon") (NYSE: ALC) and expressing its disappointment in the Company's Board of Directors' (the "Board") continued pursuit of the deal: As shareholders of STAAR Surgical for the past decade, we remain convicted in the long-term potential of the Company and are disappointed that the Board has continued to pursue the ill-advised sale to Alcon, which we do not believe is in the best interests of STAAR shareholders and does not represent adequate value for the Company.
businesswire.com
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported that independent industry analysts have recognized the value provided to STAAR stockholders by the Company's amended merger agreement with Alcon (SIX/NYSE: ALC) and the merits of the Alcon transaction. The Alcon merger agreement, as revised on December 9, 2025, provides that STAAR stockh.
businesswire.com
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has issued a new report and revised its recommendation with respect to STAAR's merger with Alcon. ISS is now recommending that all STAAR stockholders vote “FOR” STAAR's amended merger agree.
benzinga.com
Yunqi Capital Limited, which holds a 5.1% stake in STAAR Surgical Company (NASDAQ: STAA), issued a letter to shareholders on Wednesday.
reuters.com
Swiss eyecare giant Alcon has lifted its bid to acquire Staar Surgical to $30.75 per share in cash, it said on Tuesday, valuing the medical technology firm at $1.6 billion.
See all news
